Blood Cancer Journal · 2023 · 45 citations · 37 references
MedicineCancer BiologyOncologyImmunotherapyMolecular OncologyOncogenesCancer EpigeneticsCancer ImmunotherapyTargeted Cancer TherapyTargeted TherapyTherapeutic ResistanceTumor Suppressor GenesCombination TherapyKnockout Mouse ModelsLymphoma ResistanceResistance To Targeted TherapySomatic MutationsSynergistic Inhibitor EffectsTherapeutic Resistance MechanismsTp53 Mutations
Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance, especially in patients harboring somatic mutations in the tumor suppressors ATM and TP53, which are accumulated as therapy resistance emerges and the disease progresses, consistent with our OncoPrint results that ATM and TP53 alterations were most frequent in relapsed/refractory (R/R) MCL. We demonstrated that protein arginine methyltransferase-5 (PRMT5) was upregulated in R/R MCL, which predicted a poor prognosis. PRMT5 inhibitors displayed profound antitumor effects in the mouse models of MCL with mutated ATM and/or TP53, or refractory to CD19-targeted CAR T-cell therapy. Genetic knockout of PRMT5 robustly inhibited tumor growth in vivo. Co-targeting PRMT5, and ATR or CDK4 by using their inhibitors showed synergistic antitumor effects both in vitro and in vivo. Our results have provided a rational combination therapeutic strategy targeting multiple PRMT5-coordinated tumor-promoting processes for the treatment of R/R MCL with high mutation burdens.
37
Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text
Medicine, Oncology, Pharmacology +17
Arginine methylation regulates the p53 response
Martin Jansson, Stephen T. Durant, Er-Chieh Cho et al. · Nature Cell Biology · 2008 · 456 citations